AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02653976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-02L (darinaparsin for injection)
Description: Darinaparsin 300 mg/m2 once daily for 5 consecutive days every 21 days
Study NCT01004965 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study NCT04801836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estetrol monohydrate 15 mg
Description: One Estetrol monohydrate (E4) 15 mg tablet once per day
Study NCT04801836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo tablet once per day
Study NCT03958500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indocyanine green fluorescent angiography intraluminally and intraperitoneally
Description: The use of indocyanine green fluorescent angiography to check bowel and anastomosis viability in standard low anterior rectal anastomosis
Study NCT02511197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-PRGD2
Description: 68Ga-NOTA-PRGD2 were injected into the patients before the PET/CT scans
Study NCT02511197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Study NCT04430049 — intervention group
Intervention type: PROCEDURE
Intervention: Covid ICU containment measures
Description: The french containment measures during Covid-19 pandemic result in a restrictive visitation for relatives in ICU
Study NCT00521092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally
Study NCT00521092 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study NCT01198340 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PC-FNB with basal administration of local anesthetics
Description: Administration of 0.2% ropivacaine for femoral nerve block with 3 ml/h of basal dose, 5ml bolus by the patient, 60 minutes of lock out time.
Study NCT01198340 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PC-FNB without basal local anesthetics
Description: Administration of 0.2% ropivacaine for femoral nerve block without basal dose, with 8 ml bolus by the patient, 60 minutes of lockout time.
Study NCT02939378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Ketogenic diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
Study NCT02939378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Standard diet
Description: Standard diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
Study NCT04184804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: The intervention package will be consisted of:~1. Introduction of organic fruits and vegetables (by replacing the conventional ones) in school lunch menus~2. Signs in school areas about organic fruits and vegetables~3. Workshops and interactive games for children~4. Seminars for parents
Study NCT04301986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosponge
Description: In a seated position, subjects will swallow the Cytosponge capsule with 150-250 mL of water. Seven minutes and 30 seconds to ten minutes after ingestion, the sponge is then withdrawn by gentle traction on the suture. After retrieval, the string is cut and the retrieved foam sphere containing the cytological specimen is immersed in fixative and stored refrigerated (1° to 12°C \[34° to 54°F\]).
Study NCT04301986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transnasal Endoscopy (TNE)
Description: In an upright position, the scope will be inserted via the nares to examine the posterior pharynx, esophagus and proximal stomach with the transnasal endoscopy approach. The scope will be withdrawn from the nares following completion of the exam.
Study NCT04301986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: Laying on the subjects' left side, the flexible endoscope is inserted through the mouth to allow visualization of the esophageal mucosa from the upper esophageal sphincter all the way to the esophagogastric junction (EGJ).
Study NCT03731936 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT01630564 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
Study NCT01630564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion
Description: Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
Study NCT01630564 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood-Derived Lymphocyte Therapy
Description: Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
Study NCT03429062 — intervention group
Intervention type: OTHER
Intervention: Personal training exercises
Description: Personal training: strengthening, stretching, endurance, balance Whole body vibration: strengthening, balance, stretching, endurance, balance
Study NCT00521092 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative study
Study NCT02713048 — intervention group
Intervention type: OTHER
Intervention: Blood sample collection
Description: Eight blood samples in each patient within 48 hours to perform Troponin I measurement.
Study NCT02732314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational OTC Cream
Study NCT02732314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cosmetic Eczema Cream
Study NCT02732314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.05% Desonide Cream
Study NCT02732314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Cream
Study NCT02732314 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Study NCT01094041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten free diet
Description: A 4-week gluten free diet provided
Study NCT01094041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten rich diet
Description: A 4-week gluten rich diet is provided
Study NCT00861458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics
Description: Single dose of 750 mg PF-00868554 as a solution and tablets.
Study NCT04091152 — intervention group
Intervention type: OTHER
Intervention: usability assessment
Description: Usability of ardoiz will be assesse using a validated usability questionnary
Study NCT03395639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Edoxaban 15 mg or 30 mg tablets for participants 12 to \<18 years of age, or 60 mg edoxaban suspension (dosed as mg/kg) for participants under 12 years of age (and optionally, 12 or older), for oral administration
Study NCT03395639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Standard of care could include low molecular weight heparin (LMWH) and/or VKA according to the clinical site's SOC treatment regimen
Study NCT01537731 — intervention group
Intervention type: PROCEDURE
Intervention: vaginal or laparoscopic hysterectomy
Description: vaginal hysterectomy or laparoscopic hysterectomy
Study NCT03113526 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: remove drain
Description: remove drain when output is less than 30ml or less than 100ml per 24-hour
Study NCT03301818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal tactile imager
Description: Patients will undergo elasticity assessment with vaginal tactile imaging the be once before surgical repair and twice after during a 3 month interval.
Study NCT05892484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Imaging
Description: Thermal Imaging device used to evaluate fracture in those presenting with proposed wrist fracture in the emergency department.
Study NCT05892484 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: X-RAY
Description: Routine X-RAY
Study NCT01546922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Patients receive either a low dose HC (0.2-0.3 mg/kg body weight) for 10 weeks followed by 10 weeks of high dose HC (0.4-0.6 mg/kg body weight) or vice versa.
Study NCT01651611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: The TTA will use motivational interviewing (MI) techniques to assess the participant's motivation and readiness to quit, suggest plans, and assist the participant in selecting a method of treatment.
Study NCT03830879 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This cohort study have any no intervention.
Study NCT01651611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling
Description: The TTA will provide information to the participant regarding evidence-based treatments for smoking cessation, including counseling and nicotine replacement therapy (NRT); assist in a quit plan; and discuss issues such as obtaining social support, staying in treatment, and dealing with lapses.
Study NCT01651611 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: The TTA will provide information to the participant regarding evidence-based treatments for smoking cessation, including counseling and nicotine replacement therapy (NRT); assist in a quit plan; and discuss issues such as obtaining social support, staying in treatment, and dealing with lapses.
Study NCT01651611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation to smoking cessation resources
Description: The TTA will assist participants in obtaining NRT and getting connected to smoking cessation counseling services, such as the Smokers' Quitline and clinic-based programs.
Study NCT01651611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social support
Description: Meetings with the TTA will be a source of social support for the participant as they attempt to quit or stay quit.
Study NCT02619682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO
Study NCT02619682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02867137 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
Study NCT01697644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 3 IU/m\^2/day. Dose adjusted approximately every 3 months. Injected subcutaneously once daily
Study NCT00468091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exendin(9-39)amide
Study NCT00468091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atropine
Study NCT01336179 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salvadora persica
Description: twice daily use, two minutes interval
Study NCT01336179 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrush
Description: Twice daily use two minutes interval
Study NCT05818527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acceledent vibrating device
Description: used to accelerated the movement of teeth during orthodontic treatment
Study NCT00217867 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animated character intervention with telephone follow-up
Description: Animated character will teach the discharge plan before discharge, then this teaching will be reinforced by computerized telephone system.
Study NCT03298412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab is administered as a continuous IV infusion.
Study NCT01216592 — intervention group
Intervention type: OTHER
Intervention: COPD treatment
Description: Patients, will be asked to continue their previous medication (GOLD guidelines) during the study. No interventional change in COPD treatment will be performed during the study.
Study NCT02619682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT02187107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC114
Description: 300 mg tablets of TMC114 ethanolate with microcrystalline cellulose, colloidal silicon dioxide, crospovidone, magnesium stearate, and Opadry® Orange
Study NCT02187107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rtv
Description: 100 mg tablet of Norvir®
Study NCT02183584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Study NCT02183584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Study NCT03838835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented equine-facilitated CBT group program
Description: Consists of CBT strategies including 1) providing psychoeducation about anxiety, 2) teaching coping strategies when anxious,and 3) identifying and addressing dysfunctional thoughts that maintain anxiety.
Study NCT03838835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU is equine-facilitated group therapy
Description: TAU is equine-facilitated group therapy at GallopNYC, which consists of horseback riding and integrates strategies to support the development of cognitive, physical, emotional, and social skills.
Study NCT03444506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molo 1 (also referred as GSP 301-2 NS)
Study NCT03444506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molo 2 (also referred as GSP 301-1 NS)
Study NCT03444506 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Study NCT03444506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DYMISTA nasal spray
Study NCT03444506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PATANASE nasal spray
Study NCT02485444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 20 IU oxytocin in 500 ml normal saline will be infused 100 ml/h i.v. after fetus is delivered
Study NCT03354039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: DMD patients randomised to verum will receive 20 mg (0.6mg/kg) of Tamoxifen daily. Treatment will be given for the total period of 48 weeks.
Study NCT03354039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Patients randomised to placebo will be administered matching placebo. Treatment will be given for the total period of 48 weeks.
Study NCT02061228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pipelle de Cornier®
Description: Women in the intervention group will undergo an endometrial biopsy on the 6th day of ovarian stimulation using a Pipelle de Cornier® (CCD International, Paris, France). This class I individually and sterile-packaged medical device, complies with Directive 93/42/European Economic Community (EEC) and is routinely used in our centre for endometrial sampling. It is comprised of a flexible disposable polypropylene suction cannula with an outer diameter of 3.1 mm and a 2.4 mm diameter opening on the distal end, on one side of the cannula. An inner plunger creates a vacuum essential for the blind endometrial biopsy. After the introduction of the Pipelle into the uterine cavity, it will be rotated 360 degrees and moved up and down four times after withdrawing the piston.
Study NCT02032329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FastFES
Description: Fast treadmill walking supplemented with FES to ankle plantarflexor and dorsiflexor muscles, using a VFT stimulation pattern. 12 weeks of 2-3x/week. Stimulation delivered using the customKYnetics study device.
Study NCT04014933 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: LASER SPECKLE FLOWGRAPHY
Description: Non-invasive, real-time imaging and measurement of ocular blood flow of the optic disc and peripapillary region
Study NCT02861937 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non surgical periodontal therapy
Description: and root planing (SRP) was performed in two to four appointments lasting approximately 60 minutes each under local anaesthesia (2% lignocaine hydrochloride with 1:2,00,000 adrenaline) using area specific Gracey periodontal curettes and an ultrasonic device. The treatment was concluded in 3 weeks. Within the duration of the study, all subjects received supportive therapy, which included professional plaque control and reinstruction of oral hygiene.
Study NCT03178110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical therapy and dynasplint
Description: Participants will receive a session of 30-45 minutes of manual therapy two times per week, for eight weeks. All participants will be instructed how to use the Dynasplint® Trismus System at home. Participants will start the use of the DTS for 10-30 minutes three times per day, every day. If the exercises are well tolerated, time will be progressively increased to 30 minutes and then intensity (force) will be increased.
Study NCT02892968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia-Iliaca Block(FIB)
Description: The target of the FIB is the potential space between the fascia iliaca and the iliacus muscle, at least 4 cm lateral to the Femoral artery. This is neither a drug nor a device.
Study NCT02892968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Nerve Block(FNB)
Description: The target of the FNB technique is the intersection of the fascia iliaca and the femoral nerve. This is neither a drug nor a device.
Study NCT02779608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraperitoneal docetaxel
Description: One peritoneal access port will be implanted in subcutaneous space of patients' abdominal wall after laparoscopic exploration.Then intraperitoneal docetaxel in 1litre normal saline will be administered through the port
Study NCT02779608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral S-1
Description: 40mg/m² twice daily on day 1-14 every 3 weeks
Study NCT02009839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meeky Mouse program
Study NCT02009839 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Computer Games
Study NCT03969472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: probiotics
Description: apply probiotic after operation
Study NCT03969472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrophysiologic Therapy
Description: Pelvic floor electrophysiological therapy is used after surgery
Study NCT00319436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentalizing Therapy for Substance Using Mothers
Description: This 12 session individual therapy aims to enhance maternal reflective functioning and soften harsh and distorted mental representations about the child. The intervention adopts a developmental progression based on attachment theory, supporting the mother in her parenting role and offering assistance with basic needs. Mothers are encouraged to reflect on their thoughts and feelings and how they affect behavior. The therapist assists mother's thinking about representations of herself as a parent and encourages her to explore opportunities for new understanding of her emotional needs. Therapist and mother explore representations of her child and their relationship in detail in order to understand their meaning and promote more balanced representations and affect regulation. Therapist and mother also explore child's emotional experiences underlying behavior. The goal is to support the mother in becoming more aware of her child's emotional needs.
Study NCT00319436 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Parent Education for Substance Using Mothers
Description: This 12 session comparison was designed to match the experimental intervention on time spent with the counselor and maternal expectations for help with parenting. PE counselors helped mothers get connected to services (e.g. medical and pediatric care, child guidance services, housing assistance, vocational training), solve problems of daily living and make parenting-related decisions. PE mothers also received a pamphlet each week on a parenting topic of their choice. Pamphlets focused on common issues in caring for infants (e.g., soothing a crying baby, managing bedtime routines, and establishing routines ) and toddlers (e.g., helping toddlers dress, managing bedtime battles, managing difficult behavior in public, and setting limits without using punishment). Pamphlets provided behavioral guidance at a 5th grade reading level without reference to underlying mental states or emotional needs.
Study NCT03897348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral medication
Study NCT03897348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide 100 mg
Description: Oral medication
Study NCT03897348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide 200 mg
Description: Oral medication
Study NCT01622920 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound transducer
Description: A hand-held ultrasound transducer will be placed on a central incisor and enamel thickness measurements recorded